Fidelity Investments’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-333
Closed -$220 5804
2024
Q2
$220 Buy
+333
New +$207 ﹤0.01% 4916
2023
Q4
Sell
-7
Closed -$5 5696
2023
Q3
$5 Sell
7
-904
-99% -$1.11K ﹤0.01% 5228
2023
Q2
$3K Buy
911
+426
+88% +$1.29K ﹤0.01% 4498
2023
Q1
$4.41K Sell
485
-78
-14% -$1.1K ﹤0.01% 4426
2022
Q4
$6.61K Buy
563
+32
+6% +$564 ﹤0.01% 4160
2022
Q3
$11K Sell
531
-93
-15% -$2.51K ﹤0.01% 4070
2022
Q2
$15K Buy
624
+212
+51% +$7.21K ﹤0.01% 3986
2022
Q1
$21K Buy
+412
New +$20.4K ﹤0.01% 4004
2021
Q4
Sell
-28
Closed -$3K 5052
2021
Q3
$3K Buy
+28
New +$2.66K ﹤0.01% 3947
2019
Q2
Sell
-73
Closed -$4K 4260
2019
Q1
$4K Buy
+73
New +$3.95K ﹤0.01% 3325

Fidelity Investments's VBIV Position: Q3 2024 in Review

Fidelity Investments sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 333 shares — an estimated $220 sold.

Fidelity Investments first reported a position in VBIV in Q1 2019 and held it in 10 quarters. The position peaked at $21K in Q1 2022. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

  • Fidelity Investments reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
  • Fidelity Investments sold 333 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $220.
  • Fidelity Investments first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2019 and held it in 10 quarters.
  • Fidelity Investments's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $21K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.